



- (51) International Patent Classification:
A61K 31/70 (2006.01)
- (21) International Application Number:
PCT/US2013/046147
- (22) International Filing Date:
17 June 2013 (17.06.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/660,633 15 June 2012 (15.06.2012) US
- (71) Applicant: **JOSLIN DIABETES CENTER, INC.**
[US/US]; One Joslin Place, Boston, MA 02215 (US).
- (72) Inventors: **FEENER, Edward**; 24 Peter Road, No. Reading, MA 01804 (US). **CLERMONT, Allen**; 316 Poskus Street, Stoughton, MA 02072 (US).
- (74) Agent: **FARRELL, Kevin M.**; Pierce Atwood LLP, 100 Summer Street, Suite 2250, Boston, Massachusetts 02110 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION

PK ASO protects Stroke-Prone Spontaneously Hypertensive (SHRsp) Rats from ICH



(57) Abstract: Disclosed herein are methods for decreasing kallikrein and treating, preventing, or ameliorating metabolic conditions in an individual in need thereof. Examples of disease conditions that can be treated, prevented, or ameliorated with the administration of antisense compounds targeted to kallikrein include obesity and diabetes. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing a metabolic condition.

Figure 1A

WO 2013/188876 A3



Published:

(88) Date of publication of the international search report:

— *with international search report (Art. 21(3))*

25 June 2015

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/046147

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/70 (2013.01)

USPC - 514/44R

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/70, 31/712, 31/7115, 31/7125; A61P 3/00, 9/00, 9/10, 9/14, 25/00; C07H 21/02, 21/04; C12Q 1/68 (2013.01)

USPC - 435/6.11, 6.18, 91.1, 375; 514/44R 14.2; 536/22.1, 23.1, 23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

CPC - A61K 38/00, 48/00; C07H 21/00; C12N 15/10; C12Q 1/6883 (2013.01)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, Google Patents, Google Scholar

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/0253949 A1 (GOLZ et al) 01 November 2010 (01.11.2010) entire document	1-7, 11, 13, 14
Y		8-10, 12
Y		8-10, 12
A		1-14
	US 2004/0097452 A1 (DOBIE et al) 20 May 2004 (20.05.2004) entire document	
	US 2011/0065757 A1 (AIELLO et al) 17 March 2011 (17.03.2011) entire document	

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 November 2013

Date of mailing of the international search report

29 NOV 2013

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/046147

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

☐

on paper

☒

in electronic form

b. (time)

☐

in the international application as filed

☐

together with the international application in electronic form

☒

subsequently to this Authority for the purposes of search

2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

Specifically, SEQ ID NOS:1-10 were searched.